Patients with SDHD-associated head-and-neck paragangliomas (HNP) are at risk for developing pheochromocytomas for which screening has been advised. To assess clinical, biochemical, and radiological outcomes of screening in a large single-center cohort of SDHD-positive patients with HNP and to address the necessity for repetitive follow-up, we evaluated 93 patients with SDHDassociated HNP (p.Asp92Tyr, p.Leu139Pro). Screening consisted of measurement of 24 h urinary excretion of catecholamines and/or their metabolites in duplicate, which was repeated with intervals of 2 years if initial biochemical screening was negative. In patients, in whom urinary excretion was above the reference limit, imaging studies with 123 I-MIBG (metaiodobenzylguanidine) scintigraphy and magnetic resonance imaging (MRI) and/or computed tomography (CT) were performed. Pheochromocytomas and extra-adrenal paragangliomas were treated surgically after appropriate blockade. Median follow-up was 4.5 years (range 0.5-19.5 years). Twenty-eight out of the 93 patients were included in our study and underwent additional imaging for pheochromocytomas/extra-adrenal paragangliomas. In 11 out of the 28 patients intra-adrenal pheochromocytomas were found. Extra-adrenal paragangliomas were discovered in eight patients. These tumors were detected during initial screening in 63% of cases, whereas 37% were detected after repeated biochemical screening. One patient was diagnosed with a biochemically silent pheochromocytoma. The high prevalence of pheochromocytomas/extra-adrenal paragangliomas in patients with SDHD-associated HNP warrants regular screening for tumors in these patients. Paragangliomas that do not secrete catecholamines might be more prevalent than previously reported. Future studies will have to establish whether routine imaging studies should be included in the screening of SDHD mutation carriers, irrespective of biochemical screening.
Introduction
Paragangliomas are frequently multifocal tumors arising from the neural crest cells associated with the autonomic nervous system. Traditionally, they are divided into head-and-neck paragangliomas (HNP) and paragangliomas located in the thorax and abdomen. Some paragangliomas produce excessive amounts of catecholamines, especially if they are located in the adrenals (pheochromocytoma). Familial paraganglioma syndromes are associated with germ-line mutations in the genes encoding subunits of mitochondrial complex II succinate dehydrogenase (SDH): SDHD, SDHC, and SDHB (van der Mey et al. 1989 , Baysal et al. 2000 , Niemann & Muller 2000 , Astuti et al. 2001 , Koch et al. 2002 , Benn & Robinson 2006 . These SDH-genes can behave as tumor suppressor genes and distinct genotype-phenotype relations have been described (Baysal et al. 2000, Koch et al. 2002 , Neumann et al. 2004 , Timmers et al. 2007b . Among these three genes, mutations in SDHD are the most frequent cause of familial HNP in The Netherlands (Baysal et al. 2000 , Taschner et al. 2001 , Neumann et al. 2004 , van Houtum et al. 2005 . Although malignant disease is most frequently associated with SDHB mutations (Neumann et al. 2004 , Timmers et al. 2007b , we recently described patients with malignant disease associated with the SDHD-c.274GOT (p.Asp92Tyr) mutation (Havekes et al. 2007) . Several studies have investigated genotype-phenotype correlations in SDHD mutation carriers and were most often multi-center referral based patients with diverse underlying SDHD mutations (Neumann et al. 2004 .
In 2005, we reported that the prevalence of catecholamine excess in our SDHD-linked HNP patients was much higher than previously appreciated (van Houtum et al. 2005) . At the time of that study, 15 out of 40 consecutive patients (37.5%) had elevated urinary catecholamine excretion and a pheochromocytoma/paraganglioma was ultimately identified in 8 out of these 15 patients (20%). In patients with SDHDlinked HNP without elevated levels of catecholamines or their metabolites, we repeat biochemical testing at intervals of 2 years. In recent years, we have followed 93 consecutive HNP patients associated with a SDHD mutation (p.Asp92Tyr, p.Leu139Pro); including the updated data of the 40 patients who were previously reported in the paper by van Houtum et al. This is one of the largest, single-center cohorts with SDHD-linked HNP. The aim of this study was to report the clinical, biochemical, and radiological outcomes in SDHDpositive patients with HNP who were screened for elevated levels of catecholamines and their metabolites. Furthermore, we address the need for repetitive follow-up in these patients.
Patients and methods
We reviewed data of all consecutive HNP patients who visited the outpatient clinic at the Department of Endocrinology since 1988. The Leiden University Medical Center is a tertiary referral center for HNP. Systematic screening for SDHD mutations was performed in those HNP patients, who agreed upon genetic testing. HNP patients who had a SDHD mutation or who had a direct family member in whom a SDHD mutation was ascertained were eligible for inclusion. Urine was collected over 24 h in duplicate under strict dietary regulations and after changing antihypertensive medication to doxazosine or withdrawal of interfering medication for several weeks. If levels of catecholamines and/or their respective O-methylated metabolites were above the reference limits (i.e., any value above the upper reference limit), additional imaging studies using 123 I-MIBG (metaiodobenzylguanidine), computed tomography (CT), and/or magnetic resonance imaging (MRI) were performed to identify the source of catecholamine overproduction. Since 2002, the initial diagnostic protocol was improved, by implementing a standard evaluation protocol with 2-year intervals.
In ninety-three out of 154 consecutive patients with HNP the SDHD mutations (p.Asp92Tyr, p.Leu139Pro) were ascertained or documented to be present in a direct family member. Thirty-three out of the 93 patients had increased excretion of urinary catecholamines and/or the O-methylated metabolites at some point during follow-up and underwent further diagnostic imaging. Although one patient revealed no elevated levels of catecholamine excretion, imaging studies were performed and a pheochromocytoma was subsequently diagnosed (patient 8). Therefore, this patient was included in our study, in total 34 patients. Four patients with increased catecholamine and/or catecholamine metabolite excretion were excluded, because increased levels were found to be caused by tricyclic antidepressants, b-blockers and/or cannabis prior to urine collection (with normalization after cessation of medication and/or drugs). Two other patients with increased excretion were excluded because the suspected small pheochromocytomas had not yet been histologically confirmed. The clinical presentations, the biochemical phenotypes, and outcome of diagnostic imaging of these 28 remaining SDHD (p.Asp92Tyr, p.Leu139Pro) patients are described in this report.
Laboratory tests
Epinephrine, norepinephrine, and dopamine excretion in 24 h urine collections were quantified by reversed HPLC by an electrochemical detector. Inter-and intraassay coefficients of variations (CV) for epinephrine were 4.3-9.0% ranging from high to low levels. For norepinephrine these data are 2.7-3.6% and for dopamine 3.1-4.8%. Vanillylmandelic acid (VMA) in urine was measured using HPLC with fluorometric detection with inter-and intra-assay CV of 2.4-9.1%. Since 2005, samples have been tested for the O-methylated catecholamine metabolites (metanephrine, normetanephrine, and 3-methoxy-tyramine) at the University Medical Center Groningen as well (Wolthers et al. 1997) . Reference ranges were: norepinephrine 0.06-0.47 mmol/24 h, epinephrine !0.16 mmol/24 h, dopamine 0.46-3.40 mmol/24 h, VMA!30 mmol/24 h, metanephrine 33-90 mmol per mol creatinine, normetanephrine 64-260 mmol per mol
B Havekes et al.: Screening in SDHD patients
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Results
HNP were present in all patients, because the presence of HNP was an inclusion criterion. All patients, except four (patients 11, 18, 21, and 26), had a positive family history for HNP. The median duration of follow-up was 4.5 year (range 0.5-19.5 years). Mean age at presentation for first screening was 46.2G12.9 years. Imaging studies for pheochromocytomas and extraadrenal paragangliomas were performed in 28 out of the 93 SDHD mutation carriers (Tables 1 and 2 ).
Genetics
Most patients in the Leiden cohort have the SDHDc.274GOT (p.Asp92Tyr) mutation, both in the included group and those without elevated catecholamine levels that were excluded from this study. Twenty-five out of the 28 SDHD-positive patients included in this study had the SDHD-c.274GOT (p.Asp92Tyr) mutation. Patients 1, 5, and 12 had a SDHD-c.416TOC (p.Leu139Pro) mutation.
Cause of elevated levels of catecholamines and/or catecholamine metabolites Details are shown in Table 2 . In 27 out of the 28 included patients, there was increased excretion of urinary catecholamines and/or their respective metabolites. In one female patient (number 8) additional 
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www.endocrinology-journals.org radiological studies were ordered by her attending physician, though she did not reveal any catecholamine excess at repeated testing. Nonetheless, MRI imaging resulted in the detection of (an unexpected) pheochromocytoma, which was confirmed by pathological examination after surgical removal. In total, intraadrenal paragangliomas (pheochromocytomas) were identified and after appropriate a-(and b-) blockade surgically removed and histologically confirmed in 11 out of the 28 patients. In six patients with elevated catecholamine and/or catecholamine metabolite excretion, extra-adrenal paragangliomas in abdomen or pelvis were found and surgically treated after appropriate blockade. Two patients (patients 18 and 19) were diagnosed with mediastinal paragangliomas, in which patient 19 was operated. In patient 28, the resected extra-adrenal lesion suspect for paraganglioma was diagnosed as schwannoma after histological investigation. Ultimately, 11 patients with HNP and increased catecholamine and/or catecholamine metabolite excretion, no pheochromocytoma or extra-adrenal paraganglioma could be identified. Per exclusionem their catecholamine levels were attributed to the presence of glomus tumors (patients 7, 10, 20, 21, 22, 23, 24, 25, 26, 27, and 28) . Uptake of 123 I-MIBG in the glomus tumor was found in seven out of these patients. Patients 10 and 26 were operated for these glomus tumors, which resulted in normalization of excretion. Patients 7 and 10 had been previously treated for a pheochromocytoma and were later suspected of having elevated catecholamine and/or catecholamine metabolite levels caused by the glomus tumor as well.
Signs and symptoms
Palpitations were mentioned in 10 out of the 28 patients. Seven of these patients were later diagnosed with either a pheochromocytoma or an extra-adrenal paraganglioma. Hypertension was found in 17 out of the 28 patients included in this study (61%). Eight patients reported diaphoresis of which five had a pheochromocytoma or extra-adrenal paraganglioma. Headaches were only mentioned by two patients, both with a pheochromocytoma. Furthermore, HNP patients frequently reported hearing loss (34%), tinnitus (28%), and dysphonia (13%). Anxiety disorders were reported in four patients, obstructive sleep apnea in two patients, Graves' disease in two patients, and one patient (number 4) was treated for a macro-prolactinoma.
Biochemical profile of urinary catecholamines and/or catecholamine metabolites
The predominant biochemical phenotype of urinary catecholamines and their metabolites in our patients is shown in Table 3 . Norepinephrine, VMA and, if tested, normetanephrine were most frequently elevated, whereas elevation of epinephrine was only detected in two patients, one of whom had a malignant bladder paraganglioma (number 17). However, metanephrines were negative in these two patients, indicating epinephrine could have been falsely elevated. As expected, the O-methylated metabolite normetanephrine was elevated in most patients with elevated norepinephrine. One patient (patient 24) had elevated excretion of normetanephrine, whereas the excretion of norepinephrine was normal. Patient 28 had elevated excretion of metanephrine with normal values for epinephrine. Excretion of 3-methoxy-tyramine was increased in 10 out of the 28 patients and was found in patients with pheochromocytomas, extra-adrenal paragangliomas, malignant disease or producing glomus tumors.
Imaging
No patients with negative imaging on whole-body MRI and/or CT have been diagnosed with a pheochromocytoma or an extra-adrenal paraganglioma during prolonged follow-up. MRI revealed one false-positive result in our series (patient 28), in whom the extraadrenal lesion proved to be a schwannoma instead of a paraganglioma. In patients with pheochromocytomas and extra-adrenal paragangliomas combined, sensitivity and specificity of 123 I-MIBG was 74 and 78% respectively. Positive and negative predictive values for pheochromocytoma and extra-adrenal lesions combined were 88 and 58% respectively. MIBG revealed false-negative results in five patients, three of whom had malignant and/or mediastinal disease. Furthermore, subtle or more intense MIBG uptake in HNP was frequently found (11 patients), either with or without abdominal uptake. Increased uptake was shown in 11 out of 12 patients on whom octreotide scintigraphy was performed.
Discussion
This large, single-center study evaluated screening for pheochromocytomas and extra-adrenal paragangliomas in 93 SDHD-associated (p.Asp92Tyr, p.Leu139Pro) HNP patients. This study confirms the high prevalence of both pheochromocytomas and extra-adrenal paragangliomas in SDHD (p.Asp92Tyr, p.Leu139Pro) Endocrine-Related Cancer (2009) 16 527-536 www.endocrinology-journals.org mutation carriers (van Houtum et al. 2005) . Excretion of urinary catecholamines and/or their O-methylated compounds above the upper reference limit was documented in 29% of the patients. Ultimately, pheochromocytomas or extra-adrenal paragangliomas were identified in 20% of all patients in addition to the HNP. Approximately, one-third of these pheochromocytomas or extra-adrenal paragangliomas were found only by repeated screening after a normal initial outcome. Our results not only document the clinical relevance of repetitive screening in SDHD mutation carriers but also suggest that there might be a larger role for imaging as a first-line investigation. SDHD mutation carriers are at risk for developing pheochromocytomas and/or extra-adrenal paragangliomas. Van Houtum et al. (2005) have previously reported an increased prevalence of pheochromocytoma in a smaller subset of HNP patients in our center. In accordance with this previous publication, we found an increased prevalence of both pheochromocytomas and extra-adrenal paragangliomas. In addition, we were not able to find a clear correlation between clinical symptoms and the presence of pheochromocytoma or extra-adrenal paraganglioma. This lack of correlation with symptoms stresses the need for patients to undergo repeated screening. We included all SDHD-associated HNP patients with increased urinary excretion of catecholamines and/or their O-methylated metabolites (i.e., any value above the upper reference limit). Although the degree of elevation in catecholamine and/or catecholamine metabolite levels should be taken into account in the diagnostic algorithm for pheochromocytoma before initializing localization studies; less compelling biochemical evidence may justify imaging studies in those patients with a strong hereditary predisposition (Pacak et al. 2007 ). Elevations of In our study, the sensitive and specific assays for O-methylated catecholamine metabolites (metanephrine and normetanephrine) were introduced for screening only in the last few years. Measurement of these metabolites in both plasma and urine is more sensitive for the diagnosis of pheochromocytoma than measurements of their parent catecholamines (Eisenhofer et al. 1998 , Lenders et al. 2002 , Sawka et al. 2003 , Pacak et al. 2007 . Although in our study, most patients had concordant results between the excretion of catecholamines, VMA, and their O-methylated metabolites, the relatively small number of (nor) metanephrine assays performed in our study limits the reliability of a comparison between those measurements. Although patients 24 and 28 had elevated levels of the O-methylated compounds (in patient 24 normetanephrine and in patient 28 metanephrine), their respective parent catecholamines were still within reference ranges, thus exemplifying their superior sensitivity. Although the later introduction of (nor-) metanephrine analyses in our study may have theoretically resulted in an underestimation of the prevalence of elevated levels catecholamines and their metabolites, and thus of the presence of paragangliomas/pheochromocytomas in the first period of the present study, this does not invalidate our conclusions with respect to the relevance of repetitive testing for catecholamines in these patients.
More challenging is the concept of the so-called 'non-secreting' or 'biochemically silent' paragangliomas (i.e., paragangliomas that do not secrete catecholamines and/or their metabolites). These tumors might not always be detected using our present standard approach starting with urine analysis. Inadvertently, patient 8 provided the proof for this hypothesis, by the finding of a pheochromocytoma, even though no increased urinary excretion of catecholamines or their metabolites had been found. We are not able to exclude the presence of paragangliomas outside the neck region in those patients with SDHD mutations who had levels of catecholamines and catecholamine metabolites within reference limits, because no imaging studies were performed in these patients. The possibility of non-secreting or mediastinal paragangliomas and the presently unclear consequences of missing one of these tumors in our SDHD-associated population (with low estimated malignancy rates of w2.5%; Havekes et al. 2007 ) will have to be taken into consideration. By contrast, because of high malignant potential, patients with an SDHB mutation are already subjected to repetitive anatomical imaging irrespective of catecholamine or catecholamine metabolite levels (Timmers et al. 2007b ). Because we suspect undetected 'non-secreting' paragangliomas to be more frequent in SDHD carriers than hitherto reported, additional studies will have to establish the value of additional routine imaging studies in screening protocols of carriers of SDHD mutations, irrespective of concurrent catecholamines or their metabolites.
The results of the present study emphasize the need to screen all SDHD mutation carriers for increased catecholamine and catecholamine metabolite excretion on a regular basis. If this approach would not have been instituted, 7 out of the 19 patients, who were diagnosed with pheochromocytomas or extra-adrenal paragangliomas in our report would have been discharged from follow-up, or not have been subjected to screening at all. Because we suspect undetected 'non-secreting' paragangliomas to be more frequent in SDHD mutation carriers than previously reported, we advocate future studies to include MRI imaging of thorax, abdomen, and pelvis as primary or routine investigations, irrespective of biochemical results, in order to establish whether routine imaging procedures should be included in future guidelines.
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